OUTPACE

What this means for you

Not registered yet, but its 17 Jan 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

99007063

Mark type

Stylized text

Filed

17 Jan 2025

Attorney of record

Sydney R. Jensen

Goods and services

• Class 042 — Scientific and technological services: Drug discovery services; pharmaceutical drug development services; product research and development; scientific research and development services; pharmaceutical research and development; development of pharmaceutical preparations and drugs; medical and scientific research and development services, namely, identification, production and development of therapeutics, cell therapies, bioengineered cells and proteins for the treatment and prevention of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; medical and scientific research and development services, namely, identification, production and development of cell therapy solutions, namely protein design and custom cell programming; scientific, medical, biotechnology, biomedical, and pharmaceutical research, development, testing and analysis services; medical and scientific research and development services, namely, protein engineering and design services; scientific and medical services, namely, human cell programming services; scientific research, development, discovery and consulting services in the fields of cell therapy and immuno-oncology; scientific research, development, engineering and testing services in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; medical research; clinical research in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; scientific research and development, scientific laboratory services, medical and scientific research, biotechnology research and synthetic biology research, all of the foregoing relating to human beings; development of pharmaceutical preparations and drugs for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; development of pharmaceutical preparations and drugs in the field of immunotherapy; development of pharmaceutical preparations and drugs in the field of cell therapy; development of pharmaceutical preparations and drugs in the field of gene therapy; medical research laboratory services, namely, biological tissue material processing and analysis in the field of cell therapy and immuno-oncology; biotechnology scientific laboratory services; scientific and medical research laboratory services; genetic engineering services, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; genetic engineering of biological cells, cellular targets, proteins, and antibodies for others; providing a website featuring information in the scientific, medical, biotechnology, biomedical, and pharmaceutical fields for the prevention and treatment of human diseases, disorders and conditions; provision of information about scientific and medical research in the field of drug discovery, development and testing; providing a website featuring information about treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of drug discovery, development and testing; provision of information about treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of prevention and treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; providing a website featuring information about prevention and treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of the prevention and treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; provision of information about prevention and treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of cell therapy and immuno-oncology; providing a website featuring information about treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of cell therapy and immuno-oncology; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing a website featuring information about treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of pharmaceuticals and clinical trials; provision of scientific and medical research information in the fields of biotechnology, biomedical, and pharmaceuticals; providing information about medical research relating to the diagnostic and therapeutic properties of pharmaceutical preparations and biologic preparations for the prevention and treatment of human diseases, disorders and conditions;

Owner

• Outpace Bio, Inc., Seattle, WA, US

Prosecution history

• 21 Nov 2025 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
• 21 Nov 2025 — LETTER OF SUSPENSION E-MAILED
• 21 Nov 2025 — SUSPENSION LETTER WRITTEN
• 01 Oct 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 01 Oct 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 01 Oct 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 03 Jul 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 03 Jul 2025 — NON-FINAL ACTION E-MAILED
• 03 Jul 2025 — NON-FINAL ACTION WRITTEN
• 27 Jun 2025 — ASSIGNED TO EXAMINER
• 17 Jan 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 17 Jan 2025 — NEW APPLICATION ENTERED